The Lancet | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA) @TheLancetTV | Uploaded June 2021 | Updated October 2024, 1 hour ago.
A video summary of the key findings from Isatuximab, carfilzomib, and dexamethasone in relapsed
multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, published in The Lancet.

Read the full article: thelancet.com/journals/lancet/article/PIIS0140-6736(21)00592-4/fulltext?dgcid=youtube_video_lancet

Visit The Lancet at thelancet.com/journals/lancet/home?dgcid=youtube_video_lancet
Find out more at thelancet.com/?dgcid=youtube_video_lancet_lancet

* * *
Continue this conversation on social! Follow us today at…
Twitter.com/TheLancet
facebook.com/TheLancetMedicalJournal
LinkedIn.com/company/the-lancet